Ogipeptins, novel inhibitors of LPS: physicochemical properties and structural elucidation

Yuki Hirota-Takahata; Shiho Kozuma; Nahoki Kuraya; Daisuke Fukuda; Mutsuo Nakajima; Toshio Takatsu; Osamu Ando

doi:10.1038/ja.2016.61

Ogipeptins, novel inhibitors of LPS: physicochemical properties and structural elucidation

J Antibiot (Tokyo). 2017 Jan;70(1):84-89. doi: 10.1038/ja.2016.61. Epub 2016 Jun 22.

Authors

Yuki Hirota-Takahata¹, Shiho Kozuma², Nahoki Kuraya², Daisuke Fukuda¹, Mutsuo Nakajima¹, Toshio Takatsu¹, Osamu Ando²

Affiliations

¹ Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan.
² Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

PMID: 27328866
DOI: 10.1038/ja.2016.61

Abstract

In the course of our screening program for inhibitors of lipopolysaccharide binding to cellular receptor CD14, a potent inhibitory activity was detected in the cultured broth of Pseudoalteromonas sp. SANK 71903. Four active compounds, ogipeptins A, B, C and D, were isolated from the cultured broth. The structures of these compounds were elucidated by physicochemical data and spectral analyses, and they were determined to be new cyclic lipopeptides.

MeSH terms

Anti-Bacterial Agents / chemistry
Anti-Bacterial Agents / isolation & purification*
Anti-Bacterial Agents / pharmacology
Lipopeptides / chemistry
Lipopeptides / isolation & purification*
Lipopeptides / pharmacology
Lipopolysaccharide Receptors / metabolism
Lipopolysaccharides / antagonists & inhibitors*
Lipopolysaccharides / metabolism
Peptides, Cyclic / chemistry
Peptides, Cyclic / isolation & purification*
Peptides, Cyclic / pharmacology
Spectrum Analysis

Substances

Anti-Bacterial Agents
Lipopeptides
Lipopolysaccharide Receptors
Lipopolysaccharides
Peptides, Cyclic